Advertisement

Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib

Abstract

We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment. A 74-year-old man with diabetes mellitus and hypertension was diagnosed with hepatocellular carcinoma associated with fatty liver. Three weeks after sorafenib therapy, at Eastern Cooperative Oncology Group performance status 3, he developed jaundice, general weakness, flapping tremor, nausea, and anorexia. Sorafenib was stopped: laboratory tests showed a relevant elevation of transaminases suggesting diagnosis of acute hepatitis. During hospital admission, the patient died of liver failure. Sorafenib is the first successful target therapy effective for advanced hepatocellular carcinoma. The most common adverse events are fatigue, hand-foot skin reaction, skin rash/desquamation, diarrhea, and hypertension, whereas liver dysfunction is uncommon. To our knowledge, this is the first patient reported in the literature with hepatocellular carcinoma related to nonalcoholic steatohepatitis who died of rapid worsening of liver function during sorafenib treatment.

Tumori 2015; 101(2): e46 - e48

Article Type: CASE REPORT

DOI:10.5301/je.5000247

Authors

Giovanni Brandi, Stefania De Lorenzo, Stefania Di Girolamo, Stefano Bellentani, Gioconda Saccoccio, Guido Biasco

Article History

Disclosures

Financial support: Volunteer Organizing Committee “Corri con Giò.”
Conflict of interest: The authors have no conflict of interest.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Department of Experimental, Diagnostic and Specialty Medicine, Sant’Orsola Malpighi Hospital, University of Bologna, Bologna - Italy
  • “G. Prodi" Interdepartmental Center for Cancer Research (C.I.R.C.), University of Bologna, Bologna - Italy
  • Liver Center, Azienda USL Modena, “Ramazzini” Hospital, Carpi, Modena - Italy
  • Department of Medicine, Azienda USL Bologna, Bologna - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.